In January 2013, Molecular Insight was acquired by Progenics Pharmaceuticals Inc. Molecular Insight had been a clinical stage specialty pharmaceutical company focused on critical unmet diagnostic and therapeutic needs of the . The company was developing a novel, proprietary, small-molecule chemistry platform to significantly impact the care of men with prostate cancer by: identifying the extent and location of the cancers spread in patients with metastatic disease; monitoring the effectiveness of chemotherapy or radiation therapy by tracking individual metastatic lesions; delivering a novel targeted systemic radiotherapy selectively to prostate tumors while sparing normal tissues. The company had been advancing its proprietary platform technology with two separate, but related, products: a clinical-stage molecular imaging agent, technetium Tc 99m trofolastat, for patients with metastatic prostate cancer that is being used in a multi-center international Phase 2 efficacy study; and a prostate cancer therapy, 131I-MIP-1095, for systemic delivery of radiotherapy. The company has also developed AZEDRA® (iobenguane I 131), a prescription medicine used to treat adult and pediatric patients 12 years and older with cancers known as pheochromocytoma and paraganglioma that are positive for the norepinephrine transporter (as determined by an iobenguane scan), and who require systemic anticancer therapy.
